MassIVE MSV000094243

Partial Public

CDKN1B (p27kip1) enhances drug tolerant persister CTCs by restricting polyploidy following mitotic inhibitors

Subscribe Comment Convert Spectra Add Reanalysis

Description

BRx82 and BRx142 were cell cultures derived from breast cancer circulating tumor cells and propagated ex-vivo. To study early changes that transpire under mitosis inhibiting chemotherapy, these cultures were subjected to a 16 hours exposure to docetaxel (10nM or DMSO as vehicle control) and then cultured for a total of 4 days. The experiments were done using an Orbitrap Fusion (proteomics) or an Orbitrap Fusion Lumos (phosphoproteomics) mass spectrometer. Multiplexing was achieved using either TMT10 reagents and the SPS-MS3 method. Basic pH reversed-phase chromatography (bRPLC) was used for off-line pre-fractionation; 12 fractions were analyzed for proteome mappings (PMID: 26700037) and 24 fractions sample for phosphoproteome mappings (PMID: 31606085). Phosphoproteome mappings were done using both HCD fragmentation with Orbitrap fragment ion detection and CID fragmentation with ion trap fragment ion detection (PMID: 29487189, PMID: 31606085). RAW files from the proteome mapping experiment are named HorwitzMaheswaranHaber_proteome_fraction01 to 12. RAW files from the phosphoproteome mapping experiment are named TMT labeling was the same for the proteomics and the phosphoproteomics experiments: BRx82_DTX-_#1 (129c) BRx82_DTX-_#2 (130n) BRx82_DTX+_#1 (127c) BRx82_DTX+_#2 (128n) BRx142_DTX-_#1 (126) BRx142_DTX-_#2 (127n) BRx142_DTX+_#1 (128c) BRx142_DTX+_#2 (129n) [doi:10.25345/C50R9MF75] [dataset license: CC0 1.0 Universal (CC0 1.0)]

Keywords: Breast cancer, circulating tumor cells, chemotherapy, docetaxel, persister cells, proteomics, phosphoproteomics, TMT, TMT10, Orbitrap Fusion, Orbitrap Lumos Fusion, SPS MS3

Contact

Principal Investigators:
(in alphabetical order) 		Daniel Haber, Massachusetts General Hospital Cancer Center and Harvard Medical School, US
Shyamala Maheswaran, Massachusetts General Hospital Cancer Center and Harvard Medical School, US
Wilhelm Haas, Massachusetts General Hospital Cancer Center and Harvard Medical School, US
Submitting User: whaas
Number of Files:
Total Size:
Spectra:
Subscribers:
 
Owner Reanalyses
Experimental Design
    Conditions:
    Biological Replicates:
    Technical Replicates:
 
Identification Results
    Proteins (Human, Remapped):
    Proteins (Reported):
    Peptides:
    Variant Peptides:
    PSMs:
 
Quantification Results
    Differential Proteins:
    Quantified Proteins:
 
Browse Dataset Files
 
FTP Download Link (click to copy):

Species

Instrument

Modifications

- Dataset Reanalyses

+ Dataset History

Click here to queue conversion of this dataset's submitted spectrum files to open formats (e.g. mzML). This process may take some time.

When complete, the converted files will be available in the "ccms_peak" subdirectory of the dataset's FTP space (accessible via the "FTP Download" link to the right).
Number of distinct conditions across all analyses (original submission and reanalyses) associated with this dataset.

Distinct condition labels are counted across all files submitted in the "Metadata" category having a "Condition" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct biological replicates across all analyses (original submission and reanalyses) associated with this dataset.

Distinct replicate labels are counted across all files submitted in the "Metadata" category having a "BioReplicate" or "Replicate" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct technical replicates across all analyses (original submission and reanalyses) associated with this dataset.

The technical replicate count is defined as the maximum number of times any one distinct combination of condition and biological replicate was analyzed across all files submitted in the "Metadata" category. In the case of fractionated experiments, only the first fraction is considered.

"N/A" means no results of this type were submitted.
Originally identified proteins that were automatically remapped by MassIVE to proteins in the SwissProt human reference database.

"N/A" means no results of this type were submitted.
Number of distinct protein accessions reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct unmodified peptide sequences reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct peptide sequences (including modified variants or peptidoforms) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Total number of peptide-spectrum matches (i.e. spectrum identifications) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins quantified across all analyses (original submission and reanalyses) associated with this dataset.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins found to be differentially abundant in at least one comparison across all analyses (original submission and reanalyses) associated with this dataset.

A protein is differentially abundant if its change in abundance across conditions is found to be statistically significant with an adjusted p-value <= 0.05 and lists no issues associated with statistical tests for differential abundance.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
This dataset may not contain all raw spectra data as originally deposited in PRIDE. It has been imported to MassIVE for reanalysis purposes, so its spectra data here may consist solely of processed peak lists suitable for reanalysis with most software.